Sonia Alonso López
YOU?
Author Swipe
View article: Incidence and Clinical Significance of Recompensation After HCV Cure
Incidence and Clinical Significance of Recompensation After HCV Cure Open
Recompensation after HCV cure is associated with substantially decreased risks of (liver-related) mortality and PVT, but not of HCC.
View article: Simvastatin and Rifaximin in Decompensated Cirrhosis
Simvastatin and Rifaximin in Decompensated Cirrhosis Open
Importance There are no useful treatments to prevent the development of severe complications of liver cirrhosis. Simvastatin and rifaximin have shown beneficial effects in liver cirrhosis. Objective To assess whether simvastatin combined w…
View article: Predictive Value of Liver Sitffness Measurement for Early Diagnosis of Veno-Occlusive Disease and Final Stem-Cell Outcomes
Predictive Value of Liver Sitffness Measurement for Early Diagnosis of Veno-Occlusive Disease and Final Stem-Cell Outcomes Open
INTRODUCTION Pre-existing comorbidities in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) impact on its outcome. Commonly used comorbidity scores, such as the Sorror index, recognize liver disease as a s…
View article: Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure
Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure Open
Background and Aims: Around 750,000 patients per year will be cured of HCV infection until 2030. Those with compensated advanced chronic liver disease remain at risk for hepatic decompensation and de novo HCC. Algorithms have been develope…
View article: Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure
Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure Open
Liver stiffness measurement (LSM) is increasingly applied as a prognostic biomarker and commonly decreases in patients with compensated advanced chronic liver disease achieving HCV cure. Although Baveno VII proposed criteria for a clinical…
View article: AKI-HRS, more than a name change for type-1 hepatorenal syndrome
AKI-HRS, more than a name change for type-1 hepatorenal syndrome Open
Acute renal failure (ARF) development is likely the most relevant event in the natural history of severely decompensated cirrhosis. It is a common complication affecting 20-49% of inpatients with decompensated cirrhosis. Also, its presence…
View article: International multicenter validation of <scp>GES</scp> score for <scp>HCC</scp> risk stratification in chronic hepatitis C patients
International multicenter validation of <span>GES</span> score for <span>HCC</span> risk stratification in chronic hepatitis C patients Open
We have recently demonstrated the ability of a simple predictive model (GES) score to determine the risk of hepatocellular carcinoma (HCC) after using direct‐acting antivirals. However, our results were restricted to Egyptian patients with…
View article: A cascade of care analysis on the elimination of hepatitis C from public hospitals in Madrid
A cascade of care analysis on the elimination of hepatitis C from public hospitals in Madrid Open
Background Direct-acting antivirals can cure ≥95% of hepatitis C virus (HCV) cases, but do not reach everyone in need. This cross-sectional study analyses the HCV cascade of care (CoC) in Madrid, Spain, in high-risk patients, to inform mic…
View article: Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long?
Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long? Open
Hepatitis C virus (HCV) chronic infection is associated with fibrosis progression, end-stage liver complications and HCC. Not surprisingly, HCV infection is a leading cause of liver-related morbidity and mortality worldwide. After sustaine…